A 4-gene signature (ATM, RB1, FANCC, ERCC2) correlates with tumor absence post-neoadjuvant chemotherapy in muscle-invasive bladder cancer. The biomarker is more effective at predicting disease ...

SunRISe-4 targets MIBC patients ineligible for or refusing cisplatin-based chemotherapy, addressing an unmet medical need. The trial evaluates TAR-200 plus cetrelimab and cetrelimab monotherapy, ...

"Overall, TAR-200 is being tested with the aim of changing the therapeutic paradigm of patients with an early bladder cancer diagnosis, including non–muscle-invasive disease and muscle-invasive ...

F-flotufolastat shows a 69% detection rate for recurrent prostate cancer in patients with PSA levels above 0.2 ng/mL post-prostatectomy. The agent demonstrates a 50% detection rate for PSAs below 0.2 ...

UTUC is a rare malignancy, primarily affecting older men, with smoking as a significant risk factor. Nephron-sparing approaches are gaining interest due to complications from nephroureterectomy and ...

Aquablation offers personalized treatment plans using real-time ultrasound and AI, distinguishing it from traditional TURP procedures. The heat-free nature of Aquablation reduces post-operative ...

SBRT shows promise in achieving progression-free survival in metastatic RCC without systemic therapy, despite limited high-level data. The absence of phase 3 trials leaves a gap in comparing SBRT ...

Aquablation with HYDROS is a transurethral water jet procedure for BPH, combining resective and non-resective therapy benefits. The HYDROS system uses AI-powered treatment planning and real-time ...

"My hope is that the results of our study improve the uptake of active surveillance, further reducing unnecessary treatments, and this, combined with the improving reflex tests, may change the ...

Lu-rhPSMA-10.1 injection demonstrated favorable radiation dosimetry and high tumor absorption in mCRPC patients, supporting progression to phase 2 trials. Phase 2 will investigate higher radioactivity ...

Talazoparib plus enzalutamide significantly improved overall survival in mCRPC patients, including those with HRR gene mutations. The treatment's safety profile aligns with known data for talazoparib ...

PD-1/PD-L1 pathways are pivotal in cancer immunotherapy, enabling tumor immune evasion by inactivating T-cells through receptor-ligand interactions. Investigational agents in BCG-naive and ...